A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome
Objective To systematically evaluate the efficacy of rituximab in the treatment of refractory nephrotic syndrome by meta-analysis.Methods This study searched the databases of PubMed, EMBASE,Cochrane Library, CNKI,WanFang and VIP to collect the clinical randomized controlled trials of rituximab in th...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Editorial Department of Journal of Clinical Nephrology
2021-01-01
|
| Series: | Linchuang shenzangbing zazhi |
| Subjects: | |
| Online Access: | http://www.lcszb.com/thesisDetails?columnId=57904769&Fpath=home&index=0 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850186855055622144 |
|---|---|
| author | Liu Wu Wang Cheng-gang Su Wen-min Jiang He Li Zi-teng Zhang Zhao Jiang Xiao-yu |
| author_facet | Liu Wu Wang Cheng-gang Su Wen-min Jiang He Li Zi-teng Zhang Zhao Jiang Xiao-yu |
| author_sort | Liu Wu |
| collection | DOAJ |
| description | Objective To systematically evaluate the efficacy of rituximab in the treatment of refractory nephrotic syndrome by meta-analysis.Methods This study searched the databases of PubMed, EMBASE,Cochrane Library, CNKI,WanFang and VIP to collect the clinical randomized controlled trials of rituximab in the treatment of refractory nephrotic syndrome.And the retrieval time was from the establishment of the database to January 2020.After the inclusion and exclusion criteria were jointly formulated by two evaluators, the literature was screened independently and the quality evaluated.Review Manager 5.3 software was utilized for meta-analysis.Results A total of 7 studies involving 409 subjects were retrieved.The results of meta-analysis showed that rituximab elevating serum albumin \[SMD=0.80,95%CI（0.27,1.34）,P<0.05\] was superior to control group and the remission rate \[RR=1.68,95%CI（1.16,2.42）,P<0.05\] was better than control group.As compared with control group, there was no significant effect on relieving urinary protein \[SMD=-0.71,95%CI（-1.45,0.03）,P>0.05\],serum creatinine \[SMD=0.18,95%CI（-0.20,0.56）,P>0.05\] or eGFR \[SMD=0.05,95%CI（-0.72,0.82）,P>0.05\].Conclusions Rituximab can effectively alleviate refractory nephrotic syndrome and elevate serum albumin.However, due to limited inclusion studies, the above conclusions should be verified by more high-quality studies. |
| format | Article |
| id | doaj-art-979a2a64cbd443b4a2c909ddcee79068 |
| institution | OA Journals |
| issn | 1671-2390 |
| language | zho |
| publishDate | 2021-01-01 |
| publisher | Editorial Department of Journal of Clinical Nephrology |
| record_format | Article |
| series | Linchuang shenzangbing zazhi |
| spelling | doaj-art-979a2a64cbd443b4a2c909ddcee790682025-08-20T02:16:14ZzhoEditorial Department of Journal of Clinical NephrologyLinchuang shenzangbing zazhi1671-23902021-01-012130731357904769A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndromeLiu WuWang Cheng-gangSu Wen-minJiang HeLi Zi-tengZhang ZhaoJiang Xiao-yuObjective To systematically evaluate the efficacy of rituximab in the treatment of refractory nephrotic syndrome by meta-analysis.Methods This study searched the databases of PubMed, EMBASE,Cochrane Library, CNKI,WanFang and VIP to collect the clinical randomized controlled trials of rituximab in the treatment of refractory nephrotic syndrome.And the retrieval time was from the establishment of the database to January 2020.After the inclusion and exclusion criteria were jointly formulated by two evaluators, the literature was screened independently and the quality evaluated.Review Manager 5.3 software was utilized for meta-analysis.Results A total of 7 studies involving 409 subjects were retrieved.The results of meta-analysis showed that rituximab elevating serum albumin \[SMD=0.80,95%CI（0.27,1.34）,P<0.05\] was superior to control group and the remission rate \[RR=1.68,95%CI（1.16,2.42）,P<0.05\] was better than control group.As compared with control group, there was no significant effect on relieving urinary protein \[SMD=-0.71,95%CI（-1.45,0.03）,P>0.05\],serum creatinine \[SMD=0.18,95%CI（-0.20,0.56）,P>0.05\] or eGFR \[SMD=0.05,95%CI（-0.72,0.82）,P>0.05\].Conclusions Rituximab can effectively alleviate refractory nephrotic syndrome and elevate serum albumin.However, due to limited inclusion studies, the above conclusions should be verified by more high-quality studies.http://www.lcszb.com/thesisDetails?columnId=57904769&Fpath=home&index=0RituximabNephrotic syndromeMeta-analysis |
| spellingShingle | Liu Wu Wang Cheng-gang Su Wen-min Jiang He Li Zi-teng Zhang Zhao Jiang Xiao-yu A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome Linchuang shenzangbing zazhi Rituximab Nephrotic syndrome Meta-analysis |
| title | A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome |
| title_full | A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome |
| title_fullStr | A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome |
| title_full_unstemmed | A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome |
| title_short | A meta-analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome |
| title_sort | meta analysis of the efficacy of rituximab in the treatment of refractory nephrotic syndrome |
| topic | Rituximab Nephrotic syndrome Meta-analysis |
| url | http://www.lcszb.com/thesisDetails?columnId=57904769&Fpath=home&index=0 |
| work_keys_str_mv | AT liuwu ametaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT wangchenggang ametaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT suwenmin ametaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT jianghe ametaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT liziteng ametaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT zhangzhao ametaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT jiangxiaoyu ametaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT liuwu metaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT wangchenggang metaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT suwenmin metaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT jianghe metaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT liziteng metaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT zhangzhao metaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome AT jiangxiaoyu metaanalysisoftheefficacyofrituximabinthetreatmentofrefractorynephroticsyndrome |